ZBIO earnings analysis
What we found in ZBIO's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Zenas reported $1.0 million of second-quarter revenue and diluted EPS of negative $1.77, while the supplied filing text does not provide gross margin, operating margin, operating cash flow, or free cash flow. Liquidity was $673.9 million as of June 30, 2026, and management expects funding through at least Q2 2029 assuming $48.7 million of ATM proceeds and potential $75.0 million milestones from each of Royalty Pharma and Pharmakon. The principal negatives are continued dependence on external financing, $75.0 million of Pharmakon debt, heightened China tariff and supply-chain exposure, and a CFO transition effective September 30, 2026.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Liquidity runway extends through Q2 2029
- Cash, cash equivalents and investments totaled $673.9 million as of June 30, 2026. Management expects this liquidity, together with $48.7 million of third-quarter ATM proceeds and potential $75.0 million milestones from each of Royalty Pharma and Pharmakon, to fund operations through at least Q2 2029.
- Revenue remained limited and EPS was negative
- Second-quarter revenue was $1.0 million and diluted EPS was negative $1.77. The filing does not provide prior-year revenue or margin figures in the supplied text, limiting trend analysis.
- Debt position and financing terms disclosed
- The company reported $75.0 million outstanding under the Pharmakon Loan Agreement as of June 30, 2026, with interest accruing at three-month SOFR subject to a 3.25% floor plus 5.75%.
- No material control deficiencies reported
- Management concluded that disclosure controls and procedures were effective at the reasonable assurance level as of June 30, 2026, and reported no changes in internal control over financial reporting that materially affected or were reasonably likely to materially affect controls.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- China tariffs and supply-chain exposure
- The company imports certain drug substance, drug product and other components from China, while its current sole obexelimab CMO, WuXi Biologics, operates in China. The filing states that tariffs imposed or announced in April 2026 on patented pharmaceutical products could increase costs and cause supply-chain disruptions.
- Debt service depends on external financing
- The company had $75.0 million outstanding under the Pharmakon Loan Agreement as of June 30, 2026, and states that operations are not expected to generate sufficient cash flow to service debt and fund necessary capital expenditures in the foreseeable future.
- Variable-rate debt creates interest risk
- A 100-basis-point adverse change in market interest rates would increase interest expense on the loan payable by approximately $0.8 million, after considering applicable minimum floors.
- CFO transition during liquidity-intensive period
- Jennifer Fox will leave her CFO and Chief Business Officer roles effective September 30, 2026. Joseph Farmer will become principal financial officer and principal accounting officer effective September 30, 2026 while the company searches for a CFO.
- Convertible notes may pressure liquidity
- The filing states that convertible-note conversions may require cash settlement and could materially adversely affect liquidity. It also notes that conversion-related reclassification could materially reduce reported working capital.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-1.77
What they said about what is next.
No numeric revenue or EPS guidance was provided. Management stated that cash, cash equivalents and investments of $673.9 million as of June 30, 2026, together with $48.7 million of third-quarter ATM proceeds and potential $75.0 million milestones from each of Royalty Pharma and Pharmakon, are expected to fund operations through at least Q2 2029.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 13, 2026
- Zenas BioPharma reported a dismal Q1 2026 with no revenue recognized, down from $10 million in the same period last year. Operating expenses totaled $77.35 million, marking a significant increase compared to $47.33…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing ZBIO makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever